AEON Biopharma (AEON) Stock Price, News & Analysis

Company Overview

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Key Stats

• Today's Range: $0.59 to $0.64
• 50-Day Range: $0.40 to $0.72
• 52-Week Range: $0.38 to $269.28
• Volume: 1.01 million shs
• Average Volume: 987,905 shs
• Market Capitalization: $7.00 million
• P/E Ratio: 3.44
• Dividend Yield: N/A
• Price Target: $360.00
• Consensus Rating: Buy

AEON Biopharma Stock Analysis - MarketRank™

AEON Biopharma scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AEON Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AEON Biopharma is 3.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of AEON Biopharma is 3.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.88.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AEON.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AEON Biopharma does not currently pay a dividend.

Dividend Growth

AEON Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for AEON.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.77

News Sentiment

AEON Biopharma has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for AEON Biopharma this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for AEON on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, AEON Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.86% of the stock of AEON Biopharma is held by insiders.

Percentage Held by Institutions

Only 22.78% of the stock of AEON Biopharma is held by institutions.

AEON Stock Analysis - Frequently Asked Questions

How have AEON shares performed this year?

AEON Biopharma's stock was trading at $38.88 at the beginning of the year. Since then, AEON shares have decreased by 98.4% and is now trading at $0.6190.
View the best growth stocks for 2025 here.

When did AEON Biopharma's stock split?

AEON Biopharma's stock reverse split on the morning of Wednesday, February 26th 2025. The 1-72 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did AEON Biopharma IPO?

AEON Biopharma (AEON) raised $75 million in an IPO on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

Who are AEON Biopharma's major shareholders?

Top institutional investors of AEON Biopharma include Dauntless Investment Group LLC (9.73%). Insiders that own company stock include Jost Fischer and Crown Holdings Grou Strathspey.
View institutional ownership trends.

How do I buy shares of AEON Biopharma?

Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AEON Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

• Today: 5/29/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AEON
• Previous Symbol: NASDAQ:AEON
• CIK: 1837607
• Web: www.aeonbiopharma.com
• Phone: 754-220-9229
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $360.00
• High Stock Price Target: $360.00
• Low Stock Price Target: $360.00
• Potential Upside/Downside: +58,058.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $298.12
• Trailing P/E Ratio: 3.44
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -994.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.12) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 11,305,000
• Free Float: 74,373,000
• Market Cap: $7.00 million
• Optionable: Not Optionable
• Beta: 0.38